Phase 2 Study of Montelukast for the Treatment of Sickle Cell Anemia
Status:
Completed
Trial end date:
2018-03-01
Target enrollment:
Participant gender:
Summary
In this feasibility trial, the investigators will compare participants treated with
montelukast and hydroxyurea to those treated with placebo and hydroxyurea for a total of 8
weeks.
Phase:
Phase 2
Details
Lead Sponsor:
Vanderbilt University Vanderbilt University Medical Center
Collaborators:
Blood Center of Wisconsin Medical College of Wisconsin Versiti